Show simple item record

AuthorConstantinides, Vasilios C.
AuthorMajbour, Nour K.
AuthorParaskevas, George P.
AuthorAbdi, Ilham
AuthorSafieh-Garabedian, Bared
AuthorStefanis, Leonidas
AuthorEl-Agnaf, Omar M.
AuthorKapaki, Elisabeth
Available date2023-08-09T11:10:49Z
Publication Date2021-01-17
Publication NameBrain Sciences
Identifierhttp://dx.doi.org/10.3390/brainsci11010119
CitationConstantinides, V. C., Majbour, N. K., Paraskevas, G. P., Abdi, I., Safieh-Garabedian, B., Stefanis, L., ... & Kapaki, E. (2021). Cerebrospinal fluid α-synuclein species in cognitive and movements disorders. Brain sciences, 11(1), 119.
URIhttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85099715661&origin=inward
URIhttp://hdl.handle.net/10576/46603
AbstractTotal CSF α-synuclein (t-α-syn), phosphorylated α-syn (pS129-α-syn) and α-syn oligomers (o-α-syn) have been studied as candidate biomarkers for synucleinopathies, with suboptimal specificity and sensitivity in the differentiation from healthy controls. Studies of α-syn species in patients with other underlying pathologies are lacking. The aim of this study was to investigate possible alterations in CSF α-syn species in a cohort of patients with diverse underlying pathologies. A total of 135 patients were included, comprising Parkinson’s disease (PD; n = 13), multiple system atrophy (MSA; n = 9), progressive supranuclear palsy (PSP; n = 13), corticobasal degeneration (CBD; n = 9), Alzheimer’s disease (AD; n = 51), frontotemporal degeneration (FTD; n = 26) and vascular dementia patients (VD; n = 14). PD patients exhibited higher pS129-α-syn/α-syn ratios compared to FTD (p = 0.045), after exclusion of samples with CSF blood contamination. When comparing movement disorders (i.e., MSA vs. PD vs. PSP vs. CBD), MSA patients had lower α-syn levels compared to CBD (p = 0.024). Patients with a synucleinopathy (PD and MSA) exhibited lower t-α-syn levels (p = 0.002; cut-off value: ≤865 pg/mL; sensitivity: 95%, specificity: 69%) and higher pS129-/t-α-syn ratios (p = 0.020; cut-off value: ≥0.122; sensitivity: 71%, specificity: 77%) compared to patients with tauopathies (PSP and CBD). There are no significant α-syn species alterations in non-synucleinopathies.
SponsorThis study was supported by Strat-up Funding to OE from Qatar Biomedical Research Institute (SF 2007–007) and Qatar National Research Fund (NPRPNo.: 8–517–3-112).
Languageen
PublisherMultidisciplinary Digital Publishing Institute (MDPI)
SubjectBeta amyloid
Biomarkers
Cerebrospinal fluid
Dementia: neurodegenerative disorders
Parkinsonism
Tau proteins
α-synuclein
TitleCerebrospinal fluid α-synuclein species in cognitive and movements disorders
TypeArticle
Issue Number1
Volume Number11
ESSN2076-3425
dc.accessType Open Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record